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Background:
The influenza antiviral surveillance is one of the key areas for influenza control. The neuraminidase inhibitors (NAI) play an important role in flu treatment
especially for high risk patients. This study aims to determine the NAI susceptibility profile of influenza A(H3) detected during 2016/2017 season in Portugal and
to evaluate the emergence of new variants by deep sequencing analysis related to NAI resistance.
Phenotypic and genotypic profile of susceptibility to 
neuraminidase inhibitors of influenza A(H3) circulating 
in Portugal during 2016/2017 season
Methods:
Nasopharyngeal swabs were collected from patients with influenza like illness (ILI) selected in primary care settings in the scope of the National Influenza
Raquel Guiomar a, Pedro Pechirra a, Inês Costa a, Patrícia Conde a, Paula Cristóvão a, Joana Mendonça b, 
Luís Vieira b, Vítor Borges c, João Paulo Gomes c
a National Influenza Reference Laboratory, Infectious Diseases Department
b Innovation and Technology Unit, Human Genetic Department
c Bioinformatics Unit, Infectious Diseases Department 
National Institute of Health Dr. Ricardo Jorge, Portugal
raquel.guiomar@insa.min-saude.pt
+351.21.7519216
orcid.org/0000-0002-4563-6315
Surveillance Program during 2016/2017 season. For 134 A(H3) viruses, isolated in MDCK-Siat1 cells, the phenotypic antiviral drug susceptibility assay to NAI
(Oseltamivir and zanamivir) was performed. Viral RNA was extracted directly from biological samples and after multiplex PCR amplification, the whole genome
was sequenced for 144 influenza A(H3) viruses by deep sequencing on a MiSeq platform. The neuraminidase gene sequences were assembled using a in-
house multi-software pipeline with a mean depth of coverage of 1144x. Multiple gene alignments and mutational analysis was performed on MEGA software
6.0. All neuraminidase sequences were submitted to Flusurver (http://flusurver.bii.a-star.edu.sg/) in order to detect any mutation associated with susceptibility
to neuraminidase inhibitors. Were analysed intra-host single nucleotide variants (iSNV) with frequencies between 1% and 50% (minority iSNVs).
Genotypic profile
- All A(H3) expressed the wild-type aa residue compatible with
NAI susceptibility.
- Analysing neuraminidase sequences we found 68 nucleotide
sites displaying minority iSNVs among 54 (37.5%) viruses
Phenotypic profile
All 134 A(H3) strains had IC50 compatible with susceptibility to both NAI. The IC50 mean values were 0,30 (IQR 0,22-0,36) for oseltamivir and 0,49 (IQR 0,40-
0,59) for zanamivir.  The IC50 were unchanged for viruses that belonged to both co-circulating genetic groups: 3C.2a (A/Hong Kong/4801/2014-like) and 
3C.2a1  (A/Bolzano/7/2016-like), although amino acid replacements were observed in NA. 
2016/2017
Influenza A(H3)
Genetic group
IC50
Oseltamivir Zanamivir
Min. Max. Median IQR Min. Max. Median IQR
All 0,12 0,49 0,3 0,22-0,36 0,24 0,89 0,49 0,40-0,59
3C.2a 0,22 0,43 0,3 0,25-0,34 0,38 0,62 0,50 0,43-0,53
3C.2a1 0,12 0,48 0,3 0,23-0,36 0,24 0,76 0,48 0,41-0,59
Results:  
Table I - Neuraminidase inhibitor susceptibility of influenza A(H3) during 2016/2017 season. IC50 values (nM) by fluorescent neuraminidase inhibition assay (MUNANA). 
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Conclusions:
All of the tested A(H3)viruses were susceptible to oseltamivir and zanamivir. Isolates
possessing iSNV`s expressed the wild-type aa residue and had IC50 compatible with NAI
susceptible. NAI`s should be considered a good therapeutic options for influenza A(H3)
infection, prioritized to high risk groups. Whole genome deep sequencing, directly from the
biological samples, proved to be a good laboratory method to monitor the emergence of
iSNV that could lead to a resistant genotype. This approach could be used in management
of influenza severe infections under NAI treatment.
Selective pressure during the course of infection could be an explanation for the observed
redundancy of amino acid positions displaying intra-host variation in more than one virus.
In addition, for one case this analysis could disclose a potential transmission event.
(Figure 1). From these 68, 7 sites revealed intra-host variation in
more than 1 sample (with the iSNV in the nucleotide position
130 being found in 4 distinct patients).
Of note, none of the detected iSNVs is associated with any of
the known resistant markers for NAI.
- This scenario at gene level corresponds to the existence of 33
minority iSNVs at amino acid level, detected in a total of 32
viruses (22.2%). Regarding amino acid sites displaying intra-
host variation in more than one patient, the following 4 amino
acid mixtures were found: S44P/F, I57T, A110D/T and R150C/S.
Remarkably, 2 out of 4 viruses revealing the S44P (nucleotide
change T130C) intra-host variation clustered in the same
phylogenetic branch at genome level, and the patients involved
are from the same city and have been sampled in the same
week. No potential transmission link could be established for the
2 other patients as the viruses involved fall in another genetic
subgroup.
For all remaining sites revealing redundancy in intra-host
variation and potential viral transmission patterns, no
transmission links could be unveiled due to the lack of
phylogenetic and epidemiological congruence.
- Still, the observed intra-host variation specifically targeting the
same amino acid position in more than one patient may suggest
that those specific protein sites are under selective pressure,
although we cannot exclude the random scenario.
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Figure 1 - Frequencies of each minority iSNV (1%-50%) found in the neuraminidase gene. In grey and 
red – synonymous and non-synonymous (amino acid-altering) iSNV’s, respectively.
